Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 19/20 | 0.71 |
| ▸ | MAOB | P27338 | 16/20 | 0.71 |
| ▸ | MAOA | P21397 | 15/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10273171 | 1.00 | KDM1A (0.71) | KDM1AMAOBMAOA | |
| SCHEMBL527626 | 1.00 | KDM1A (0.71) | KDM1AMAOBMAOA | |
| SCHEMBL530177 | 0.87 | KDM1A (0.77) | KDM1AMAOBMAOA | |
| SCHEMBL530178 | 0.87 | KDM1A (0.77) | KDM1AMAOBMAOA | |
| SCHEMBL15235912 | 0.87 | KDM1A (0.77) | KDM1AMAOBMAOA | |
| SCHEMBL10272884 | 0.86 | KDM1A (0.71) | KDM1AMAOBMAOA | |
| SCHEMBL528209 | 0.86 | KDM1A (0.71) | KDM1AMAOBMAOA | |
| SCHEMBL528210 | 0.86 | KDM1A (0.71) | KDM1AMAOBMAOA | |
| SCHEMBL10272661 | 0.84 | KDM1A (0.80) | KDM1AMAOBMAOA | |
| SCHEMBL528071 | 0.84 | KDM1A (0.80) | KDM1AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180284095-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | ORYZON GENOMICS SA (ES) | 2018-10-04 | — | — | US | claimed |
| EP-3375775-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | Oryzon Genomics, S.A. (ES) | 2018-09-19 | — | — | EP | claimed |
| US-20150376177-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2015-12-31 | — | — | US | claimed |
| US-20130231342-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | Oryzon Fenomics S.A. (ES) | 2013-09-05 | — | — | US | claimed |
| EP-2598482-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | Oryzon Genomics, S.A. (ES) | 2013-06-05 | — | — | EP | claimed |
| CN-103124724-A | Arylcyclopropylamine-based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS SA | 2013-05-29 | — | — | CN | claimed |
| WO-2012013728-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2012-02-02 | — | — | WO | claimed |
| EP-3430015-B1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2025-08-06 | — | — | EP | disclosed |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2025-01-14 | — | — | US | disclosed |
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2022-12-08 | — | — | US | disclosed |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-06-24 | — | — | US | disclosed |
| US-11034991-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2021-06-15 | — | — | US | disclosed |
| EP-3716963-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD1 BINDING ANTAGONIST | Epiaxis Therapeutics Pty Ltd (AU) | 2020-10-07 | — | — | EP | disclosed |
| WO-2016198649-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | ORYZON GENOMICS, S.A. (ES) | 2016-12-15 | — | — | WO | disclosed |
| US-20150376177-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2015-12-31 | — | — | US | disclosed |
| US-9181198-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS S.A. (ES) | 2015-11-10 | — | — | US | disclosed |
| US-20130231342-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | Oryzon Fenomics S.A. (ES) | 2013-09-05 | — | — | US | disclosed |
| EP-2598482-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | Oryzon Genomics, S.A. (ES) | 2013-06-05 | — | — | EP | disclosed |
| CN-103124724-A | Arylcyclopropylamine-based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS SA | 2013-05-29 | — | — | CN | disclosed |
| WO-2012013728-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOB 3928/4885MAOA 4155/4885 |
| US-20180284095-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | KDM1B, EZH2, DOT1L | KDM1A 5/4885MAOB 410/4885MAOA 526/4885 |
| US-20130231342-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | KDM6A, KDM1B, KDM1A | KDM1A 3/4885MAOB 66/4885MAOA 52/4885 |
| US-20150376177-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | KDM6A, KDM1B, KDM1A | KDM1A 3/4885MAOB 66/4885MAOA 52/4885 |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | PDCD1, CD274, PDCD1LG2 | KDM1A 8/4885MAOB 36/4885MAOA 54/4885 |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOB 3928/4885MAOA 4155/4885 |
| US-11034991-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOB 3928/4885MAOA 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.